Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

LLMC 2020 | Oral therapies in the future of AML treatment

Sangmin Lee • 21 Oct 2020
LLMC 2020
Acute Myeloid Leukemia Azacitidine Venetoclax
QUAZAR AML-001

Sangmin Lee, MD, Weill Cornell Medical College, New York City, NY, discusses the future of acute myeloid leukemia (AML) treatment, highlighting the approval of oral azacitidine as a maintenance therapy for patients undergoing induction chemotherapy who are not eligible for curative therapy as a result of the Phase III QUAZAR AML-001 trial (NCT01757535). Dr Lee also discusses how future research will focus on developing oral hypomethylating agents to be used in combination with oral venetoclax. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Disclosures

Consultancy: AstraZeneca, BMS, Jazz, Roche Diagnostics
DSMB membership: Helsinn

More from Sangmin Lee

1:45
Updates on the treatment of MDS
Sangmin Lee • 20 Oct 2021
1:07
Challenges in treating AML
Sangmin Lee • 20 Oct 2021
1:13
Rare blood diseases at LLM 2021
Sangmin Lee • 20 Oct 2021
2:10
Updated overall survival data on eltanexor for HMA-refractory MDS
Sangmin Lee • 4 Jun 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals